Rapamycin vs. Metformin
mTOR Inhibition vs AMPK Activation — The Longevity Drug Debate
Rapamycin and metformin are the two most discussed longevity drugs in geroscience. They work through different but partially overlapping pathways, carry distinct risk profiles, and appeal to different users. Here is the rigorous comparison that longevity researchers actually debate.
Rapamycin: Suppressing Growth to Extend Life
mTOR (mechanistic target of rapamycin) is the master growth-and-build regulator. High mTOR activity drives the cell growth and protein synthesis needed for youth — but chronically elevated mTOR in aging promotes cellular senescence, impairs autophagy, and accelerates age-related pathology. Rapamycin puts the brakes on mTORC1, triggering autophagy and mimicking many effects of caloric restriction at the cellular level.
Metformin: Promoting Repair Over Growth
AMPK is the cellular energy sensor — activated when energy is low (as in fasting or exercise). Metformin activates AMPK, which shifts cell metabolism from anabolic (growth) to catabolic (repair) mode, reduces hepatic glucose output, improves insulin sensitivity, and inhibits mTOR indirectly. Its effects broadly mimic aspects of caloric restriction and exercise adaptation.
Full Comparison: Rapamycin vs Metformin
Who Should Choose Which?
Choose Rapamycin If…
- ✓You are a healthy individual without T2D who is pursuing longevity specifically and has physician oversight willing to prescribe off-label.
- ✓You are persuaded by the ITP mouse lifespan data — the strongest mammalian longevity evidence for any single compound.
- ✓You train heavily and are concerned about metformin blunting exercise adaptations — weekly rapamycin dosing may be less disruptive than daily AMPK activation.
- ✓You follow the Bryan Johnson Protocol or are aligned with the biohacker community around mTOR inhibition.
Choose Metformin If…
- ✓You have type 2 diabetes or prediabetes — metformin remains the first-line standard of care with decades of validated safety.
- ✓You want the most evidence-based longevity drug in terms of human safety data — 60+ years and tens of millions of patients globally.
- ✓You want to participate in or align with the TAME trial framework — the only FDA Breakthrough-designated aging clinical trial.
- ✓Cost matters — metformin is $4–15/month versus $50–200 for rapamycin from compounding pharmacies.
Stacking Rapamycin + Metformin
Bryan Johnson — whose Blueprint protocol is probably the most rigorous self-experimentation in longevity history — takes both rapamycin and metformin. The rationale is pathway complementarity: rapamycin directly suppresses mTORC1, while metformin inhibits mTOR indirectly through AMPK and also provides glucose and insulin benefits that rapamycin does not.
Some preclinical evidence suggests additive or synergistic effects on longevity pathways when both are combined. However, rapamycin does have modest glucose-raising effects (it impairs insulin secretion via mTORC1 in beta cells), and metformin can partially counteract this — making the combination metabolically complementary.
The main practical concerns with stacking: rapamycin's immunosuppressive effect (even at low weekly doses, wound healing may be slightly impaired), metformin's GI burden, and the need for physician monitoring of both glucose and immune markers. This combination is not a DIY protocol.
FAQ
Why did Peter Attia stop taking metformin?
Peter Attia publicly stopped metformin after becoming concerned about evidence that it blunts exercise adaptations — specifically, that it may reduce mitochondrial biogenesis and muscle protein synthesis in response to resistance training. A 2019 study in Nature Aging showed metformin attenuated the increase in insulin sensitivity and mitochondrial function that typically follows aerobic exercise training in older adults. For highly active individuals whose longevity strategy centers on exercise, this is a meaningful tradeoff.
How does rapamycin extend lifespan in mice?
The ITP (Interventions Testing Program) is a rigorously controlled multi-site NIA-funded program testing compounds in genetically heterogeneous mice. Rapamycin showed 9% lifespan extension in males and 14% in females in the original 2009 study — even when started at an age equivalent to 60 years in humans. Subsequent ITP cohorts confirmed and extended these findings, with some cohorts showing up to 23% increase in median lifespan. Mechanistically, rapamycin inhibits mTORC1, reducing protein synthesis and promoting autophagy — the cellular recycling process that degrades damaged components and is strongly associated with longevity across species.
Can you take rapamycin and metformin together?
Yes, and this combination is used by some longevity-focused physicians and patients including Bryan Johnson. The mechanisms are partially complementary: rapamycin inhibits mTORC1 directly while metformin activates AMPK, which also inhibits mTOR indirectly. Some researchers argue the combination provides broader pathway coverage. The practical concerns are GI side effects from metformin and the immunosuppressive risk of rapamycin — which at the 3–6mg/week doses used for longevity purposes is substantially lower than the daily dosing used in transplant medicine, but not zero.
Track Your Longevity Protocol
Shotlee helps you log weekly rapamycin doses, daily metformin, and all your longevity supplements — with dose history, weight tracking, and health metrics in one free app.
Download Shotlee Free